EGFR and esophageal adenocarcinoma: In 2021, Chen and colleagues (40) reported the use of two heptapeptides (Cy5-labeled QRHKPRE, EGFR-specific, and IRDye800-labeled KSPNPRF, ErbB2-specific) given simultaneously during FME to visualize Barrett’s esophagus (NCT03589443).